MedPage Today) -- A dose-reduction strategy for a commonly used first-line combination in pancreatic cancer resulted in similar survival outcomes but improved tolerability, a randomized phase II study showed. In patients with stable disease following...
.png)
Copyright © 2023 cape-breton.com. Toady's News. All Rights Reserved
